Noxopharm jumps as flagship lupus drug clears first-pass in vitro safety tests

Noxopharm (ASX:NOX) has reported its lupus medication in development, SOF-SKN, has passed first-stage in vitro safety tests before clinical trials.

The stock jumped 11% out the gate, to 10cps, on thin trades on Tuesday.

Lupus is an autoimmune condition that turns the body’s defences against it, ultimately culminating in organ and tissue damage.

Noxopoharm’s SOF-SKN is a topical treatment targeting specific receptors in the body, particularly a receptor called TLR7 which is believed to be associated with the autoimmune condition. SOF-SKN is a topical gel and is described as a Sofra drug candidate.

In vitro tests have now shown, in line with international standards, that the drug is unlikely to cause genetic mutations or cardiac toxicity. In vitro tests effectively work on tissue samples in Petri dishes or similar environments.

Another study also examined the drug’s reaction to UV light, which came up clear. Think exposure to sunlight after applying the cream.

One final study is required ahead of human clinical trials set for 2025.

“Successfully passing these safety tests takes us a significant step closer to the clinic. They give us confidence that SOF-SKN will be safe for use in the HERACLES trial, and we will continue our preparations as quickly and efficiently as possible,” Noxopharm CEO Dr. Gisela Mautner said.

NOX last traded at 8.5cps.

Join the discussion: See what HotCopper users are saying about Noxopharm and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.